Featured Articles
FORMULATION FORUM - PLGA – A Versatile Copolymer for Design & Development of Nanoparticles for Drug Delivery
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the chemistry, properties, applications, and regulatory aspects of PLGA, and the future trends in the industry, especially those requiring the development of long-acting injectables for the treatment of a variety of rare diseases and for life cycle management.
DRUG DEVELOPMENT - Overcoming Challenges on the Path From Candidate Selection to First-in-Human Clinical Testing
Eleanor Row, PhD, explores the current challenges drug developers face in transitioning their candidate molecules to first-in-human (FIH) clinical trials, including what the different drug development functions should be considering at this stage, and how an integrated approach can help to accelerate your molecule’s pathway to trial and beyond.
EXECUTIVE INTERVIEW - Jubilant HollisterStier: The Importance of Expertise in Sterile Fill Finish
Chris Preti, President of Jubilant HollisterStier, discusses how the CMO is handling increased demand for sterile fill finish and how expertise makes a difference to customer relationships and finished product quality.
DEVICE DEVELOPMENT - How to Ensure pMDI Drug Products Are Fit for the Future Market Landscape
Ross Errington explores the latest developments in the pMDI segment and explains the steps pharmaceutical companies need to take to ensure their pMDI drug products are ready to thrive in a very different market environment.
EXECUTIVE INTERVIEW - Lifecore Biomedical: Emerging From Under the Radar
Darren Hieber discusses his company’s progress after his first year as Sr. Vice President of Corporate Development and Partnerships at Lifecore Biomedical.
EXCIPIENT TECHNOLOGY - A Juggling Act: Factors at Play in Your Choice of Solubilizing Parenteral Excipients
Joey Glassco, MBA, says the power of novel excipients such as Apisolex polymer could revolutionize the parenteral drug development landscape, effectively solubilizing a wide range of APIs without compromising on safety or stability.
CLINICAL TRIALS - How Conversational Data & Listening at Scale Improve Clinical Recruitment
Amy Brown says one of the most effective ways to gather valuable, relevant, and useful information from a clinical trial is by listening to conversations at scale, helping researchers understand the psychosocial factors influencing and affecting a specific patient population.
ANTI-VIRAL RESEARCH - Anti-Viral Activity of Pimpinella anisum Extract In Vitro Study
Fouad Al-Bayaty, Mazen M. Jamil Al-Obaidi, Maryam Haki Al-Doori, and Omar Imad present a study conducted to evaluate the antiviral effectiveness of Pimpinella anisum against dengue virus.
FORMULATION FORUM - LIPIDSOL®: Liposomes - Chemistry, Properties & Applications of Lipid Nanoparticles
Jim Huang, PhD, and Shaukat Ali, PhD, describe their LNP platform as well as the latest trends in LNPs as more and more novel therapeutic modalities discovered can’t be handled by traditional microemulsions or nanoemulsions.
SPECIAL FEATURE - Parenteral Drug Delivery: Could a Dose of AI Improve Development?
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
IMMUNOLOGY - Innovation Gathers Momentum Amid New Scientific & Technological Breakthroughs
Patrick Larcier, PhD, says research is entering a new era in immunology with treatments for pathologies that previously had few or no options and looks at the latest trends and what is on the horizon for 2023 and beyond.
ION EXCHANGE EXCIPIENTS - Tackling Patient Compliance With Oral Drug Formulations Using Ion Exchange Resins
Amie Gehris explains how IERs solve various pharmaceutical formulation issues, including decreasing the bitter taste of many pharmaceutical drugs, improving patient outcomes by supporting compliance to treatment regimens, and providing new revenue streams for pharmaceutical companies.
DELIVERY DEVICES - Growing Connected Market Set to Elevate Healthcare Outcomes
Michael Earl examines what the connected device market will look to achieve in the coming years and how it is likely to drive improved adherence to treatments and improve overall healthcare outcomes.
EXECUTIVE INTERVIEW - Novadip Biosciences: Developing a New Class of Regenerative Tissue Products to Accelerate Healing of Critical Size Bone Defects, Trauma & Spinal Problems
Denis Dufrane, MD, PhD, Chief Executive Officer, and Founder of Novadip Biosciences, discusses his company’s innovative approach to tissue regeneration technology.
DRUG-ELUTING SYSTEMS - Introducing Drugs to Silicone & Controlling Elution Rates
Zach Fletcher explains how an experienced manufacturing partner can help therapy developers quickly identify solutions and develop manufacturing and formulation methods for use in many applications.
EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
VACCINE TECHNOLOGY - Solving the Challenges & Introducing New Strategies for Influenza & COVID-19 Protection
Paul Radspinner, MBA, and Pamuk Bilsel, PhD, say with a combination vaccination strategy, the biopharma industry could truly solve the efficacy, durability, and drift problems of current influenza and COVID-19 vaccines.
(e-book) The Oral Dosage Drug Delivery Market 2023
Place Your Oral Formulation In Experienced Hands Download: The Oral Dosage Drug Delivery Market. Thank you for your interest in Pii and our eBook on…
INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors
Bryan Oronsky, PhD, says traditionally, pharmaceutical development is based on the “magic bullet” concept of “one drug, one target, one disease.” However, with the growing realization that chronic inflammation lies at the center of many, if not all, diseases, it is possible to envision inflammasome inhibitors, which reduce or prevent inflammation, as near-universal treatment panaceas.
SPECIAL FEATURE - Excipients: Their Future Could Lie in Generics
Contributor Cindy H. Dubin highlights the innovative work being done by several leading companies and exemplifies the importance of excipients to the future of drug development.